These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

202 related articles for article (PubMed ID: 26852561)

  • 1. [New antitubercular agents are not where where we need them to be].
    Nau JY
    Rev Med Suisse; 2015 Dec; 11(499):2408-9. PubMed ID: 26852561
    [No Abstract]   [Full Text] [Related]  

  • 2. India plans to expand access to new tuberculosis drug.
    Sharma DC
    Lancet; 2017 Feb; 389(10070):685. PubMed ID: 28229866
    [No Abstract]   [Full Text] [Related]  

  • 3. Bedaquiline or delamanid for rifampin-resistant tuberculosis?
    Lessem E; Cox V; Furin J
    Lancet Respir Med; 2017 Oct; 5(10):772-774. PubMed ID: 28887015
    [No Abstract]   [Full Text] [Related]  

  • 4. Combined treatment of drug-resistant tuberculosis with bedaquiline and delamanid: a systematic review.
    Pontali E; Sotgiu G; Tiberi S; Tadolini M; Visca D; D'Ambrosio L; Centis R; Spanevello A; Migliori GB
    Eur Respir J; 2018 Jul; 52(1):. PubMed ID: 29903862
    [No Abstract]   [Full Text] [Related]  

  • 5. Bedaquiline and delamanid in combination for treatment of drug-resistant tuberculosis.
    Mohr E; Ferlazzo G; Hewison C; De Azevedo V; Isaakidis P
    Lancet Infect Dis; 2019 May; 19(5):470. PubMed ID: 31034392
    [No Abstract]   [Full Text] [Related]  

  • 6. Compassionate use of delamanid in combination with bedaquiline for the treatment of multidrug-resistant tuberculosis.
    Hafkin J; Hittel N; Martin A; Gupta R
    Eur Respir J; 2019 Jan; 53(1):. PubMed ID: 30361253
    [No Abstract]   [Full Text] [Related]  

  • 7. Compassionate and optimum use of new tuberculosis drugs.
    Matteelli A; D'Ambrosio L; Centis R; Tadolini M; Migliori GB
    Lancet Infect Dis; 2015 Oct; 15(10):1131-1132. PubMed ID: 26461941
    [No Abstract]   [Full Text] [Related]  

  • 8. Acquired Resistance to Bedaquiline and Delamanid in Therapy for Tuberculosis.
    Bloemberg GV; Keller PM; Stucki D; Trauner A; Borrell S; Latshang T; Coscolla M; Rothe T; Hömke R; Ritter C; Feldmann J; Schulthess B; Gagneux S; Böttger EC
    N Engl J Med; 2015 Nov; 373(20):1986-8. PubMed ID: 26559594
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Compassionate and optimum use of new tuberculosis drugs.
    Reed C; Mason L; Cox H; Seaworth B; Lessem E; Furin J
    Lancet Infect Dis; 2015 Oct; 15(10):1131. PubMed ID: 26461942
    [No Abstract]   [Full Text] [Related]  

  • 10. Bedaquiline plus delamanid for XDR tuberculosis.
    Lachâtre M; Rioux C; Le Dû D; Fréchet-Jachym M; Veziris N; Bouvet E; Yazdanpanah Y
    Lancet Infect Dis; 2016 Mar; 16(3):294. PubMed ID: 26973310
    [No Abstract]   [Full Text] [Related]  

  • 11. Barriers to new drug development in respiratory disease.
    Brigden G; du Cros P; Wong S
    Eur Respir J; 2016 Jan; 47(1):356-7. PubMed ID: 26721975
    [No Abstract]   [Full Text] [Related]  

  • 12. Drug-resistance mechanisms and tuberculosis drugs.
    Köser CU; Javid B; Liddell K; Ellington MJ; Feuerriegel S; Niemann S; Brown NM; Burman WJ; Abubakar I; Ismail NA; Moore D; Peacock SJ; Török ME
    Lancet; 2015 Jan; 385(9965):305-7. PubMed ID: 25706840
    [No Abstract]   [Full Text] [Related]  

  • 13. Cost-effectiveness of incorporating bedaquiline into a treatment regimen for MDR/XDR-TB in Germany.
    Wolfson LJ; Gibbert J; Wirth D; Diel R
    Eur Respir J; 2015 Dec; 46(6):1826-9. PubMed ID: 26493796
    [No Abstract]   [Full Text] [Related]  

  • 14. The STREAM trial: missed opportunities and lessons for future clinical trials.
    Loveday M; Reuter A; Furin J; Seddon JA; Cox H
    Lancet Infect Dis; 2019 Apr; 19(4):351-353. PubMed ID: 30910428
    [No Abstract]   [Full Text] [Related]  

  • 15. Access to new medications for the treatment of drug-resistant tuberculosis: patient, provider and community perspectives.
    Lessem E; Cox H; Daniels C; Furin J; McKenna L; Mitnick CD; Mosidi T; Reed C; Seaworth B; Stillo J; Tisile P; von Delft D
    Int J Infect Dis; 2015 Mar; 32():56-60. PubMed ID: 25809757
    [TBL] [Abstract][Full Text] [Related]  

  • 16. First case of extensively drug-resistant tuberculosis treated with both delamanid and bedaquiline.
    Tadolini M; Lingtsang RD; Tiberi S; Enwerem M; D'Ambrosio L; Sadutshang TD; Centis R; Migliori GB
    Eur Respir J; 2016 Sep; 48(3):935-8. PubMed ID: 27288039
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Global programmatic use of bedaquiline and delamanid for the treatment of multidrug-resistant tuberculosis.
    Cox V; Brigden G; Crespo RH; Lessem E; Lynch S; Rich ML; Waning B; Furin J
    Int J Tuberc Lung Dis; 2018 Apr; 22(4):407-412. PubMed ID: 29562988
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Global Progress and Challenges in Implementing New Medications for Treating Multidrug-Resistant Tuberculosis.
    Furin J; Brigden G; Lessem E; Rich M; Vaughan L; Lynch S
    Emerg Infect Dis; 2016 Mar; 22(3):. PubMed ID: 26885674
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The World Health Organization global aDSM database: generating evidence on the safety of new treatment regimens for drug-resistant tuberculosis.
    Halleux CM; Falzon D; Merle C; Jaramillo E; Mirzayev F; Olliaro P; Weyer K
    Eur Respir J; 2018 Mar; 51(3):. PubMed ID: 29567719
    [No Abstract]   [Full Text] [Related]  

  • 20. BPaL approved for multidrug-resistant tuberculosis.
    Burki T
    Lancet Infect Dis; 2019 Oct; 19(10):1063-1064. PubMed ID: 31559963
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 11.